Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine
Latest Information Update: 04 Nov 2021
At a glance
- Drugs AGS v (Primary) ; Montanide ISA-51
- Indications Dengue; Malaria; Viral infections; West Nile virus infections; Zika virus infection
- Focus Adverse reactions; First in man; Pharmacodynamics
Most Recent Events
- 19 Jun 2020 Results published in the Internet Document
- 19 Jun 2020 New trial record